In this issue:
Enfortumab vedotin + pembrolizumab for locally advanced/metastatic urothelial cancer
Durvalumab + olaparib in metastatic urothelial carcinoma
Rucaparib following chemo for metastatic urothelial carcinoma
Cost-effectiveness of ddMVACx6 vs. GCx4 before radical cystectomy for muscle-invasive bladder cancer
Chemoradiotherapy + cetuximab for muscle-invasive bladder cancer
Characteristics of patients who remain untreated for non-metastatic muscle-invasive bladder cancer
Molecular associations of recurrence in high-risk non-muscle invasive bladder cancer following BCG failure
Improvements in survival for advanced urothelial carcinoma after introduction of pembrolizumab
Pembrolizumab & nab-paclitaxel for platinum-refractory/cisplatin-ineligible advanced urothelial cancer
Time to ICI initiation & outcomes with second-line ICI in advanced urothelial carcinoma
Please login below to download this issue (PDF)